These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 23744355)

  • 41. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.
    Phadke MS; Sini P; Smalley KS
    Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.
    Peh J; Fan TM; Wycislo KL; Roth HS; Hergenrother PJ
    Mol Cancer Ther; 2016 Aug; 15(8):1859-69. PubMed ID: 27297867
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
    Shi H; Kong X; Ribas A; Lo RS
    Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.
    Chen J; Fiskus W; Eaton K; Fernandez P; Wang Y; Rao R; Lee P; Joshi R; Yang Y; Kolhe R; Balusu R; Chappa P; Natarajan K; Jillella A; Atadja P; Bhalla KN
    Blood; 2009 Apr; 113(17):4038-48. PubMed ID: 19074726
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.
    Sinnberg T; Makino E; Krueger MA; Velic A; Macek B; Rothbauer U; Groll N; Pötz O; Czemmel S; Niessner H; Meier F; Ikenberg K; Garbe C; Schittek B
    EBioMedicine; 2016 Jun; 8():132-149. PubMed ID: 27428425
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
    Sueda T; Sakai D; Kawamoto K; Konno M; Nishida N; Koseki J; Colvin H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Satoh T; Doki Y; Mori M; Ishii H
    Sci Rep; 2016 Jan; 6():18949. PubMed ID: 26750638
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
    Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
    Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
    Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN
    J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
    Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
    Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
    Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB
    Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
    Corcoran RB; Rothenberg SM; Hata AN; Faber AC; Piris A; Nazarian RM; Brown RD; Godfrey JT; Winokur D; Walsh J; Mino-Kenudson M; Maheswaran S; Settleman J; Wargo JA; Flaherty KT; Haber DA; Engelman JA
    Sci Transl Med; 2013 Jul; 5(196):196ra98. PubMed ID: 23903755
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
    Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
    [No Abstract]   [Full Text] [Related]  

  • 53. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.
    Landreville S; Agapova OA; Matatall KA; Kneass ZT; Onken MD; Lee RS; Bowcock AM; Harbour JW
    Clin Cancer Res; 2012 Jan; 18(2):408-16. PubMed ID: 22038994
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
    Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
    Kundu A; Quirit JG; Khouri MG; Firestone GL
    Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.
    Sharma A; Shah SR; Illum H; Dowell J
    Drugs; 2012 Dec; 72(17):2207-22. PubMed ID: 23116250
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.
    Das Thakur M; Salangsang F; Landman AS; Sellers WR; Pryer NK; Levesque MP; Dummer R; McMahon M; Stuart DD
    Nature; 2013 Feb; 494(7436):251-5. PubMed ID: 23302800
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL.
    Carson R; Celtikci B; Fenning C; Javadi A; Crawford N; Carbonell LP; Lawler M; Longley DB; Johnston PG; Van Schaeybroeck S
    Clin Cancer Res; 2015 Jul; 21(14):3230-3240. PubMed ID: 25813020
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.
    Narita Y; Okamoto K; Kawada MI; Takase K; Minoshima Y; Kodama K; Iwata M; Miyamoto N; Sawada K
    Mol Cancer Ther; 2014 Apr; 13(4):823-32. PubMed ID: 24448821
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
    Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J
    PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.